Evogene (EVGN) SEC Filings: History & Chart

Evogene Ltd.(EVGN)

Biotechnology · Rehovot, HM

$0.43+0.02 (+5.88%)

Delayed quote: Oct 6, 2026, 1:57 PM EDT

About Evogene Ltd.

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Rehovot, HM

52 employees

www.evogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ofer Haviv

View full financials

Form	Filing Date	Accepted	Document
4	Sep 30, 2026	Sep 30, 2026	View filing
4	Sep 30, 2026	Sep 30, 2026	View filing
4	Sep 30, 2026	Sep 30, 2026	View filing
4	Sep 30, 2026	Sep 30, 2026	View filing
6-K	Sep 30, 2026	Sep 30, 2026	View filing
EFFECT	Sep 29, 2026	Sep 30, 2026	View filing
6-K	Sep 28, 2026	Sep 28, 2026	View filing
POS AM	Sep 28, 2026	Sep 28, 2026	View filing
6-K	Sep 15, 2026	Sep 15, 2026	View filing
SC 13D/A	Sep 11, 2026	Sep 11, 2026	View filing
SC 13D/A	Sep 11, 2026	Sep 11, 2026	View filing
6-K	Sep 4, 2026	Sep 4, 2026	View filing
SC 13D/A	Aug 28, 2026	Aug 28, 2026	View filing
6-K	Aug 27, 2026	Aug 27, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
6-K	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13D/A	Aug 13, 2026	Aug 13, 2026	View filing
SC 13D/A	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 13, 2026	Aug 13, 2026	View filing
SC 13D	Aug 11, 2026	Aug 11, 2026	View filing
SC 13D/A	Aug 7, 2026	Aug 7, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
6-K	Jul 31, 2026	Jul 31, 2026	View filing
SC 13D/A	Jul 27, 2026	Jul 27, 2026	View filing
SC 13D/A	Jul 20, 2026	Jul 20, 2026	View filing
424B5	Jul 17, 2026	Jul 17, 2026	View filing
6-K	Jul 17, 2026	Jul 17, 2026	View filing
SC 13D	Jul 10, 2026	Jul 10, 2026	View filing
6-K	Jun 16, 2026	Jun 16, 2026	View filing

SEC Filings

Recent Filings